CARDIOVASCULAR BENEFITS OF CANAGLIFLOZIN USE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN INTEGRATIVE REVIEW

Abstract

SGLT2 inhibitors were developed as glucose-lowering agents for patients with type 2 diabetes mellitus (T2DM), acting through the inhibition of sodium and glucose reabsorption, which results in their urinary excretion. Studies have shown that this class of medications provides significant cardiovascular and renal health benefits. The aim of this review was to analyze the positive effects of Canagliflozin on the cardiac function of diabetic patients. The search was conducted on the PubMed and Virtual Health Library platforms, selecting 23 articles after applying the inclusion criteria (publications between 2019 and 2024, complete, free access, and classified as clinical trials or controlled clinical trials) and exclusion criteria (studies that did not address the cardiovascular effects of Canagliflozin, duplicates, or lacking a consistent theoretical basis). In 19 studies, the results indicate consistent benefits, especially in patients with heart failure, showing reductions in symptoms, hospitalizations, and mortality. Moreover, these studies demonstrated that adverse effects were not higher than those observed with placebo. It is concluded that Canagliflozin, although further research is needed, is a safe and effective medication for improving cardiovascular health in individuals with type 2 diabetes.